Cahaba Wealth Management, Inc. Bristol Myers Squibb CO Transaction History

Cahaba Wealth Management, Inc.

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Apr 22, 2024	SELL	$47.98 - $54.4 $4,366 - $4,950	-91 Reduced 2.3%	3,872 $209,000
Q4 2023 Jan 23, 2024	SELL	$48.48 - $57.85 $26,179 - $31,239	-540 Reduced 11.99%	3,963 $203,000
Q3 2023 Oct 18, 2023	SELL	$57.89 - $64.73 $114,332 - $127,841	-1,975 Reduced 30.49%	4,503 $261,000
Q2 2023 Jul 26, 2023	BUY	$63.71 - $70.74 $84,670 - $94,013	1,329 Added 25.81%	6,478 $414,000
Q1 2023 May 04, 2023	SELL	$65.71 - $74.53 $2,234 - $2,534	-34 Reduced 0.66%	5,149 $356,000
Q4 2022 Jan 30, 2023	BUY	$68.48 - $81.09 $273 - $324	4 Added 0.08%	5,183 $372,000
Q3 2022 Oct 18, 2022	SELL	$0.13 - $76.84 $10 - $5,916	-77 Reduced 1.46%	5,179 $368,000
Q2 2022 Jul 19, 2022	SELL	$72.62 - $79.98 $9,803 - $10,797	-135 Reduced 2.5%	5,256 $404,000
Q1 2022 May 05, 2022	BUY	$61.48 - $73.72 $8,115 - $9,731	132 Added 2.51%	5,391 $405,000
Q4 2021 Feb 01, 2022	BUY	$53.63 - $62.52 $79,426 - $92,592	1,481 Added 39.2%	5,259 $328,000
Q3 2021 Oct 15, 2021	BUY	$59.17 - $69.31 $223,544 - $261,853	3,778 New	3,778 $223,000

2,533

1.47B

31.6M

35M

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $125B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

Get notified when there are updates to the investment portfolio of Cahaba Wealth Management, Inc., based on Form 13F filings with the SEC.

Stay updated on Cahaba Wealth Management, Inc. with notifications on news.